Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOX | P28300 | 19/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1415463 | 0.81 | LOX (0.39) | LOXLOXL2MAOA | |
| SCHEMBL6672357 | 0.78 | SMN1; SMN2 (0.40) | LOXLOXL2TDP1 | |
| SCHEMBL5649583 | 0.77 | KMT2A (0.37) | LOXLOXL2L3MBTL1 | |
| SCHEMBL3005886 | 0.76 | L3MBTL1 (0.43) | LOXLOXL2MAOAL3MBTL1 | |
| SCHEMBL7132351 | 0.73 | L3MBTL1 (0.46) | LOXTDP1L3MBTL1 | |
| SCHEMBL10684316 | 0.73 | TDP1 (0.39) | TDP1L3MBTL1 | |
| SCHEMBL956744 | 0.72 | ALDH1A1 (0.41) | LOXLOXL2MAOAL3MBTL1 | |
| SCHEMBL3012976 | 0.72 | L3MBTL1 (0.58) | LOXLOXL2MAOAAPOBEC3AAPOBEC3G | |
| SCHEMBL27869688 | 0.72 | FAAH (0.39) | LOXAPOBEC3AAPOBEC3GTDP1ERAP1 | |
| SCHEMBL6968634 | 0.70 | LOX (0.50) | LOXLOXL2MAOATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049620-A1 | Cyclic tertiary amine compound | SANKYO COMPANY, LIMITED (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1632488-A1 | CYCLIC TERTIARY AMINE COMPOUND | Sankyo Company, Limited (JP) | 2006-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049620-A1 | Cyclic tertiary amine compound | MYD88, IL5, BRD4 | LOX 4450/4885LOXL2 4717/4885MAOA 2395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.